Adial Pharmaceuticals (NASDAQ:ADIL) Trading 3.1% Higher

Adial Pharmaceuticals, Inc. (NASDAQ:ADILGet Free Report) traded up 3.1% during mid-day trading on Monday . The stock traded as high as $1.09 and last traded at $1.08. 31,383 shares were traded during mid-day trading, a decline of 99% from the average session volume of 3,206,165 shares. The stock had previously closed at $1.05.

Adial Pharmaceuticals Price Performance

The company’s 50-day moving average price is $1.33 and its 200-day moving average price is $1.50.

Adial Pharmaceuticals (NASDAQ:ADILGet Free Report) last announced its earnings results on Tuesday, May 14th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). Sell-side analysts forecast that Adial Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

Hedge Funds Weigh In On Adial Pharmaceuticals

An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADILFree Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. 16.41% of the stock is owned by hedge funds and other institutional investors.

Adial Pharmaceuticals Company Profile

(Get Free Report)

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.

Further Reading

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.